Kim B G, Moon J Y, Choi J Y, Park I S, Oh A Y, Jeon Y T, Hwang J W, Ryu J H
Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Korea.
Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Gumiro 173 Beon-Gil, Bundang-gu, Seongnam, 13620, Korea.
World J Surg. 2018 Jul;42(7):2094-2101. doi: 10.1007/s00268-017-4421-9.
Acute postoperative pain and chronic discomfort are reported after robotic or endoscopic thyroidectomy. The purpose of this prospective, randomized, and double-blinded clinical trial was to investigate whether intraoperative infusion of nefopam decreases acute postoperative pain and chronic discomfort following either a robotic or endoscopic thyroidectomy via the bilateral axillo-breast approach (BABA).
Patients were randomized into two groups: The control group (n = 29) or the nefopam group (n = 29). Patients in each group were infused with the same volume of saline or nefopam (0.2 mg/kg bolus, 120 μg/kg/h continuous infusion) during surgery. Acute postoperative pain, the need for rescue analgesics, and other postoperative adverse effects were assessed at 1, 6, 24, and 48 h postoperatively. Chronic pain and discomfort was recorded at 3 months after surgery.
Patients in the nefopam group reported lower pain scores in the neck, as well as the axilla and anterior chest areas at 1, 6, 24, and 48 h postoperatively, when compared with the control group (P < 0.05 at each time points). Rescue analgesics were required less in the nefopam group than in the control group (1.4 [1] vs. 2.3 [1.5]; P = 0.001). The degree of chronic pain and discomfort were relatively lower in the nefopam group (P < 0.05).
We report that intravenous nefopam infusion during surgery decreased acute postoperative pain and the need for rescue analgesics, as well as chronic discomfort, following BABA robotic or endoscopic thyroidectomy without adverse events.
机器人或内镜甲状腺切除术后会出现急性术后疼痛和慢性不适。这项前瞻性、随机、双盲临床试验的目的是研究术中输注奈福泮是否能减轻经双侧腋窝-乳房入路(BABA)的机器人或内镜甲状腺切除术后的急性术后疼痛和慢性不适。
患者被随机分为两组:对照组(n = 29)和奈福泮组(n = 29)。每组患者在手术期间输注相同体积的生理盐水或奈福泮(0.2 mg/kg推注,120 μg/kg/h持续输注)。术后1、6、24和48小时评估急性术后疼痛、使用急救镇痛药的需求及其他术后不良反应。术后3个月记录慢性疼痛和不适情况。
与对照组相比,奈福泮组患者在术后1、6、24和48小时颈部、腋窝和前胸区域的疼痛评分更低(各时间点P < 0.05)。奈福泮组使用急救镇痛药的需求少于对照组(1.4 [1] 比2.3 [1.5];P = 0.001)。奈福泮组慢性疼痛和不适的程度相对较低(P < 0.05)。
我们报告称,在BABA机器人或内镜甲状腺切除术中静脉输注奈福泮可减轻急性术后疼痛、减少使用急救镇痛药的需求以及慢性不适,且无不良事件发生。